- Home
- FFC vs PRAX Comparison
FFC vs PRAX Comparison
Compare FFC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- PRAX
- Stock Information
- Founded
- FFC 1983
- PRAX 2015
- Country
- FFC United States
- PRAX United States
- Employees
- FFC N/A
- PRAX N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- PRAX Health Care
- Exchange
- FFC Nasdaq
- PRAX Nasdaq
- Market Cap
- FFC 781.9M
- PRAX 730.1M
- IPO Year
- FFC N/A
- PRAX 2020
- Fundamental
- Price
- FFC $15.93
- PRAX $38.66
- Analyst Decision
- FFC
- PRAX Strong Buy
- Analyst Count
- FFC 0
- PRAX 10
- Target Price
- FFC N/A
- PRAX $123.80
- AVG Volume (30 Days)
- FFC 164.1K
- PRAX 537.5K
- Earning Date
- FFC 01-01-0001
- PRAX 05-12-2025
- Dividend Yield
- FFC 6.79%
- PRAX N/A
- EPS Growth
- FFC N/A
- PRAX N/A
- EPS
- FFC N/A
- PRAX N/A
- Revenue
- FFC N/A
- PRAX $8,553,000.00
- Revenue This Year
- FFC N/A
- PRAX N/A
- Revenue Next Year
- FFC N/A
- PRAX $2,780.59
- P/E Ratio
- FFC N/A
- PRAX N/A
- Revenue Growth
- FFC N/A
- PRAX 249.53
- 52 Week Low
- FFC $11.90
- PRAX $30.01
- 52 Week High
- FFC $14.96
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- FFC 45.24
- PRAX 36.27
- Support Level
- FFC $16.03
- PRAX $33.10
- Resistance Level
- FFC $16.20
- PRAX $39.22
- Average True Range (ATR)
- FFC 0.15
- PRAX 2.45
- MACD
- FFC -0.01
- PRAX 1.52
- Stochastic Oscillator
- FFC 31.25
- PRAX 83.99
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.